Back to AZN
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in ER-Positive HER2-Negative Breast Cancer
View Full LandscapeDrug Information
Target Indication
ER-Positive HER2-Negative Breast Cancer
Clinical Trial
NCT04711252Last updated: 1/2/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts